Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Pesquisa Study Connect
  • NCT07101094

Not Yet Recruiting

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU) - CN012-0066

Atualizado: 19 agosto, 2025   |   ClinicalTrials.gov

Imprima o Resumo

CONSIDERANDO ESTE ESTUDO?
Imprima esta página e o guia de estudo para ajudá-lo a conversar com seu médico.
Use o guia de estudo para navegar no processo de participação em um estudo clínico. Entenda os principais fatores a serem considerados antes de decidir e faça perguntas para sua equipe de saúde.
Imprimir esta página CN012-0066
Baixar o guia

SELECIONAR IDIOMA

Detalhes do estudo

  • Gênero(s)

  • 18+

    Faixa etária

  • 7

    Localização(ões)

  • Not Yet Recruiting

Opções de tratamento

Braços de tratamento do Estudo
INTERVENÇÃO ATRIBUÍDA
Participants receiving xanomeline and trospium chloride (XT) therapy
Drug: xanomeline and trospium chloride (XT) therapy

Principais critérios de elegibilidade

Inclusion Criteria: - Aged ≥18 years at index date. - Have a confirmed diagnosis of schizophrenia before index date. - Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy. - Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. - Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish). - English or Spanish speaking. Exclusion Criteria: - Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening. - Evidence of use of XT prior to time of eligibility screening.

É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas

Tem dúvidas? Envie-nos um email.

Tem dúvidas?
Envie-nos um email.